Index RUT P/E - EPS (ttm) -3.75 Insider Own 11.34% Shs Outstand 69.61M Perf Week 5.30%
Market Cap 3.89B Forward P/E - EPS next Y -4.77 Insider Trans -6.74% Shs Float 66.61M Perf Month 107.19%
Income -237.22M PEG - EPS next Q -1.16 Inst Own 92.34% Short Float 5.45% Perf Quarter 75.37%
Sales 0.00M P/S - EPS this Y -37.36% Inst Trans 4.56% Short Ratio 3.03 Perf Half Y 93.87%
Book/sh 10.61 P/B 4.89 EPS next Y -20.04% ROA -32.66% Short Interest 3.63M Perf Year 139.78%
Cash/sh 9.55 P/C 5.43 EPS next 5Y -19.08% ROE -35.90% 52W Range 17.86 - 58.40 Perf YTD 86.34%
Dividend Est. - P/FCF - EPS past 5Y 1.03% ROI -30.65% 52W High -11.23% Beta -0.22
Dividend TTM - Quick Ratio 17.25 Sales past 5Y 0.00% Gross Margin - 52W Low 190.26% ATR (14) 2.81
Dividend Ex-Date - Current Ratio 17.25 EPS Y/Y TTM -59.03% Oper. Margin - RSI (14) 65.39 Volatility 3.71% 6.05%
Employees 56 Debt/Eq 0.05 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 78.27
Option/Short Yes / Yes LT Debt/Eq 0.05 EPS Q/Q -46.82% Payout - Rel Volume 0.71 Prev Close 50.58
Sales Surprise - EPS Surprise -19.49% Sales Q/Q - Earnings Nov 08 BMO Avg Volume 1.20M Price 51.84
SMA20 1.39% SMA50 40.63% SMA200 78.90% Trades
Volume 851,968 Change 2.49%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-30-25 Upgrade BofA Securities
Neutral → Buy
$35 → $63
Jan-27-25 Reiterated H.C. Wainwright
Buy
$50 → $72
Nov-18-24 Initiated Citigroup
Buy
$65
Apr-22-24 Resumed BofA Securities
Neutral
$30
Sep-19-23 Initiated Cantor Fitzgerald
Overweight
$69
Aug-28-23 Initiated UBS
Buy
$83
Jan-27-23 Upgrade Morgan Stanley
Equal-Weight → Overweight
$40 → $65
Sep-14-22 Upgrade Evercore ISI
In-line → Outperform
$10 → $50
Oct-19-21 Downgrade Morgan Stanley
Overweight → Equal-Weight
$27
Sep-10-21 Initiated BofA Securities
Buy
$40
Feb-26-21 Initiated Guggenheim
Buy
$54
Sep-10-20 Initiated Morgan Stanley
Overweight
$70
Jul-20-20 Reiterated H.C. Wainwright
Buy
$45 → $62
Jul-07-20 Initiated Chardan Capital Markets
Buy
$79
Jul-01-20 Reiterated H.C. Wainwright
Buy
$33 → $45
Mar-02-20 Initiated H.C. Wainwright
Buy
$33
Feb-10-20 Initiated Canaccord Genuity
Buy
$36
Jul-15-19 Initiated ROTH Capital
Buy
$34
Jul-15-19 Initiated JP Morgan
Overweight
$28
Jul-15-19 Initiated Jefferies
Buy
$28
Show Previous Ratings
Feb-20-25 08:42AM
Feb-19-25 02:45PM
Feb-03-25 07:25PM
12:28PM
Feb-02-25 06:21PM
04:35PM
Loading…
04:35PM
Jan-30-25 04:05PM
Jan-29-25 05:39AM
Jan-28-25 09:30PM
11:14AM
08:40AM
Jan-27-25 04:24PM
(Investor's Business Daily) +97.52%
04:01PM
12:13PM
11:27AM
11:10AM
Loading…
11:10AM
10:57AM
09:01AM
06:30AM
Jan-24-25 04:05PM
Jan-13-25 07:00AM
Jan-09-25 12:18PM
Jan-07-25 07:00AM
Dec-04-24 12:59PM
Nov-26-24 07:00AM
Nov-15-24 11:00AM
Nov-13-24 04:05PM
Nov-12-24 11:00PM
Nov-08-24 07:00AM
Nov-02-24 12:00PM
04:06AM
Loading…
Nov-01-24 04:06AM
Oct-30-24 06:00AM
Oct-21-24 07:00AM
Oct-17-24 03:02PM
Oct-16-24 08:44AM
Oct-15-24 06:10PM
Sep-30-24 07:00AM
Sep-12-24 01:12AM
Sep-09-24 07:00AM
Sep-05-24 12:02AM
Sep-02-24 05:22PM
Aug-28-24 04:05PM
Aug-09-24 02:53PM
07:00AM
Jul-16-24 12:00PM
Jun-28-24 10:40AM
Jun-24-24 01:04PM
Jun-21-24 11:06AM
Jun-19-24 02:45PM
Jun-17-24 10:23AM
Jun-13-24 03:57PM
09:00AM
Jun-11-24 07:00AM
Jun-10-24 10:14AM
Jun-08-24 08:15AM
Jun-06-24 10:39AM
Jun-03-24 09:57AM
May-30-24 09:16PM
May-29-24 07:00AM
May-23-24 02:12PM
May-15-24 09:26AM
May-12-24 09:01PM
May-10-24 01:54PM
07:45AM
07:00AM
May-08-24 07:00AM
Apr-30-24 08:00AM
Apr-22-24 06:00AM
Mar-20-24 01:32PM
12:58PM
Mar-18-24 07:00AM
(The Wall Street Journal)
Mar-08-24 04:02PM
Mar-07-24 04:01PM
Mar-06-24 11:54PM
Mar-05-24 09:13PM
02:12PM
Mar-04-24 04:21PM
04:04PM
(Investor's Business Daily)
12:30PM
(The Wall Street Journal)
11:59AM
09:23AM
(Investor's Business Daily)
06:22AM
06:09AM
06:00AM
04:00AM
Mar-01-24 09:55AM
Feb-29-24 08:00AM
07:00AM
Feb-06-24 10:48AM
Feb-05-24 09:55AM
Jan-30-24 09:40AM
Jan-03-24 08:15AM
Dec-18-23 07:00AM
Dec-13-23 03:06AM
Dec-05-23 01:34PM
12:36PM
Nov-14-23 07:21PM
Nov-13-23 07:00AM
Nov-10-23 08:57AM
Nov-08-23 07:00AM
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Yale Catriona Chief Development Officer Feb 18 '25 Option Exercise 21.10 10,000 211,000 105,648 Feb 21 05:31 PM Yale Catriona Chief Development Officer Feb 18 '25 Sale 49.87 10,000 498,660 95,648 Feb 21 05:31 PM Cheng Andrew President and CEO Feb 10 '25 Sale 52.73 30,000 1,581,994 686,062 Feb 11 09:30 PM Graham G. Walmsley Director Jan 30 '25 Buy 48.00 200,000 9,600,000 1,000,000 Feb 07 07:54 PM Rolph Timothy Chief Scientific Officer Feb 05 '25 Option Exercise 21.10 18,750 395,625 188,987 Feb 07 06:05 PM Rolph Timothy Chief Scientific Officer Feb 05 '25 Sale 56.51 18,750 1,059,630 170,237 Feb 07 06:05 PM Young Jonathan Chief Operating Officer Feb 03 '25 Sale 53.81 10,000 538,061 251,147 Feb 05 09:03 AM Yale Catriona Chief Development Officer Jan 27 '25 Option Exercise 10.48 53,590 561,807 149,238 Jan 31 09:14 AM Yale Catriona Chief Development Officer Jan 27 '25 Sale 56.25 53,590 3,014,216 95,648 Jan 31 09:14 AM Yale Catriona Chief Development Officer Jan 27 '25 Option Exercise 21.10 49,074 1,035,461 144,722 Jan 31 09:14 AM Yale Catriona Chief Development Officer Jan 27 '25 Sale 55.72 49,074 2,734,212 95,648 Jan 31 09:14 AM Rolph Timothy Chief Scientific Officer Jan 27 '25 Option Exercise 20.51 31,250 640,942 201,487 Jan 29 08:43 PM Rolph Timothy Chief Scientific Officer Jan 27 '25 Sale 55.77 31,250 1,742,958 170,237 Jan 29 08:43 PM Lamy Patrick Senior VP, Commercial Strategy Jan 27 '25 Option Exercise 19.87 4,000 79,480 38,492 Jan 29 08:43 PM Lamy Patrick Senior VP, Commercial Strategy Jan 27 '25 Sale 57.03 5,000 285,150 33,492 Jan 29 08:43 PM Cheng Andrew President and CEO Jan 27 '25 Sale 54.90 30,000 1,646,978 716,062 Jan 29 08:43 PM Young Jonathan Chief Operating Officer Jan 24 '25 Option Exercise 6.36 43,064 274,059 261,147 Jan 27 06:08 PM Cheng Andrew President and CEO Jan 23 '25 Option Exercise 0.61 50,000 30,750 746,062 Jan 27 06:07 PM CATRIONA YALE Officer Jan 27 '25 Proposed Sale 26.18 53,591 1,403,012 Jan 27 04:24 PM CATRIONA YALE Officer Jan 27 '25 Proposed Sale 26.18 69,073 1,808,331 Jan 27 04:24 PM PATRICK D LAMY Officer Jan 27 '25 Proposed Sale 26.18 6,000 157,080 Jan 27 04:23 PM Andrew Cheng President, CEO and Director Jan 27 '25 Proposed Sale 57.03 120,000 6,843,600 Jan 27 04:19 PM Timothy Rolph Officer Jan 27 '25 Proposed Sale 57.03 68,750 3,920,813 Jan 27 04:06 PM Young Jonathan Chief Operating Officer Jan 02 '25 Sale 28.03 10,000 280,330 218,083 Jan 06 02:08 PM Jonathan Young Officer Jan 02 '25 Proposed Sale 27.82 70,000 1,947,400 Jan 02 04:29 PM Lamy Patrick Senior VP, Commercial Strategy Dec 16 '24 Sale 29.13 1,000 29,130 34,258 Dec 18 09:03 PM Yale Catriona Chief Development Officer Dec 16 '24 Option Exercise 21.10 9,074 191,461 104,722 Dec 18 09:01 PM Yale Catriona Chief Development Officer Dec 16 '24 Sale 29.11 9,074 264,117 95,648 Dec 18 09:01 PM Rolph Timothy Chief Scientific Officer Dec 17 '24 Option Exercise 19.87 3,800 75,506 182,137 Dec 18 08:52 PM Rolph Timothy Chief Scientific Officer Dec 17 '24 Sale 31.10 3,800 118,172 178,337 Dec 18 08:52 PM PATRICK D LAMY Officer Dec 16 '24 Proposed Sale 28.89 1,000 28,890 Dec 16 04:30 PM Rolph Timothy Chief Scientific Officer Dec 10 '24 Option Exercise 19.87 2,450 48,682 180,787 Dec 12 08:44 PM Rolph Timothy Chief Scientific Officer Dec 10 '24 Sale 30.91 4,818 148,934 178,337 Dec 12 08:44 PM Young Jonathan Chief Operating Officer Dec 10 '24 Sale 30.79 2,503 77,067 203,783 Dec 12 08:38 PM Lamy Patrick Senior VP, Commercial Strategy Dec 10 '24 Sale 30.79 925 28,481 17,858 Dec 12 08:29 PM Yale Catriona Chief Development Officer Dec 10 '24 Sale 30.79 2,810 86,520 71,348 Dec 12 08:28 PM White William Richard Chief Financial Officer Dec 10 '24 Sale 30.79 2,817 86,735 38,335 Dec 12 08:26 PM Cheng Andrew President and CEO Dec 10 '24 Sale 30.79 7,855 241,855 597,562 Dec 12 08:24 PM Timothy Rolph Officer Dec 10 '24 Proposed Sale 30.79 25,000 769,750 Dec 10 04:25 PM Cheng Andrew President and CEO Dec 02 '24 Option Exercise 21.10 25,000 527,500 630,417 Dec 04 07:36 PM Cheng Andrew President and CEO Dec 02 '24 Sale 32.09 25,000 802,250 605,417 Dec 04 07:36 PM Young Jonathan Chief Operating Officer Dec 02 '24 Sale 32.13 10,000 321,310 206,286 Dec 04 07:34 PM Yale Catriona Chief Development Officer Nov 15 '24 Option Exercise 21.10 9,061 191,187 83,219 Nov 19 09:57 PM Yale Catriona Chief Development Officer Nov 15 '24 Sale 27.73 9,061 251,274 74,158 Nov 19 09:57 PM Yale Catriona Chief Development Officer Nov 06 '24 Option Exercise 0.61 10,000 6,150 84,158 Nov 08 05:06 PM Yale Catriona Chief Development Officer Nov 06 '24 Sale 35.19 10,000 351,890 74,158 Nov 08 05:06 PM CATRIONA YALE Officer Nov 06 '24 Proposed Sale 32.74 10,000 327,400 Nov 06 05:01 PM Young Jonathan Chief Operating Officer Nov 01 '24 Option Exercise 21.09 40,716 858,700 267,002 Nov 05 09:04 AM Young Jonathan Chief Operating Officer Nov 01 '24 Sale 31.57 50,716 1,601,252 216,286 Nov 05 09:04 AM Cheng Andrew President and CEO Nov 01 '24 Option Exercise 21.10 108,366 2,286,523 686,697 Nov 05 09:00 AM Cheng Andrew President and CEO Nov 01 '24 Sale 31.73 108,366 3,438,312 605,417 Nov 05 09:00 AM Yale Catriona Chief Development Officer Nov 01 '24 Option Exercise 21.10 15,485 326,734 89,643 Nov 01 08:59 PM Yale Catriona Chief Development Officer Oct 30 '24 Option Exercise 21.10 4,515 95,266 78,673 Nov 01 08:59 PM Yale Catriona Chief Development Officer Nov 01 '24 Sale 32.62 15,485 505,105 74,158 Nov 01 08:59 PM Yale Catriona Chief Development Officer Oct 30 '24 Sale 32.53 4,515 146,855 74,158 Nov 01 08:59 PM CATRIONA YALE Officer Nov 01 '24 Proposed Sale 30.83 29,074 896,351 Nov 01 04:46 PM Cheng Andrew President and CEO Oct 18 '24 Option Exercise 21.10 63,539 1,340,673 668,956 Oct 18 08:57 PM Cheng Andrew President and CEO Oct 16 '24 Option Exercise 21.10 24,992 527,331 630,409 Oct 18 08:57 PM Cheng Andrew President and CEO Oct 17 '24 Option Exercise 21.10 3,103 65,473 608,520 Oct 18 08:57 PM Cheng Andrew President and CEO Oct 18 '24 Sale 31.53 63,539 2,003,328 605,417 Oct 18 08:57 PM Cheng Andrew President and CEO Oct 16 '24 Sale 31.14 24,992 778,151 605,417 Oct 18 08:57 PM Cheng Andrew President and CEO Oct 17 '24 Sale 31.12 3,103 96,559 605,417 Oct 18 08:57 PM Young Jonathan Chief Operating Officer Oct 14 '24 Option Exercise 21.09 40,000 843,600 266,286 Oct 16 08:06 PM Young Jonathan Chief Operating Officer Oct 14 '24 Sale 30.15 40,000 1,206,080 226,286 Oct 16 08:06 PM Yale Catriona Chief Development Officer Oct 15 '24 Option Exercise 0.61 14,825 9,117 90,119 Oct 16 08:06 PM Yale Catriona Chief Development Officer Oct 14 '24 Option Exercise 0.61 5,000 3,075 80,294 Oct 16 08:06 PM Yale Catriona Chief Development Officer Oct 15 '24 Sale 30.50 14,825 452,232 75,294 Oct 16 08:06 PM Yale Catriona Chief Development Officer Oct 14 '24 Sale 30.03 6,136 184,258 74,158 Oct 16 08:06 PM Andrew Cheng President, CEO and Director Oct 16 '24 Proposed Sale 29.82 225,000 6,709,500 Oct 16 04:50 PM CATRIONA YALE Officer Oct 15 '24 Proposed Sale 30.01 32,960 989,130 Oct 15 04:38 PM CATRIONA YALE Officer Oct 14 '24 Proposed Sale 29.63 6,136 181,810 Oct 15 08:04 AM Young Jonathan Chief Operating Officer Oct 01 '24 Sale 28.18 10,000 281,770 226,286 Oct 03 08:09 PM Jonathan Young Officer Oct 01 '24 Proposed Sale 28.51 110,716 3,156,513 Oct 01 04:03 PM Yale Catriona Chief Development Officer Sep 20 '24 Option Exercise 0.61 5,500 3,382 80,794 Sep 23 06:00 PM Yale Catriona Chief Development Officer Sep 20 '24 Sale 27.65 5,500 152,086 75,294 Sep 23 06:00 PM Yale Catriona Chief Development Officer Sep 18 '24 Option Exercise 0.61 3,871 2,381 79,165 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 16 '24 Option Exercise 0.61 2,485 1,528 77,779 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 17 '24 Option Exercise 0.61 2,037 1,253 77,331 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 18 '24 Sale 27.56 3,871 106,685 75,294 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 16 '24 Sale 27.52 2,485 68,375 75,294 Sep 18 09:19 PM Yale Catriona Chief Development Officer Sep 17 '24 Sale 27.55 2,037 56,115 75,294 Sep 18 09:19 PM CATRIONA YALE Officer Sep 16 '24 Proposed Sale 27.34 13,893 379,835 Sep 16 04:34 PM Young Jonathan Chief Operating Officer Sep 10 '24 Sale 26.18 568 14,870 236,286 Sep 13 05:16 PM Yale Catriona Chief Development Officer Sep 10 '24 Sale 26.18 637 16,677 75,294 Sep 13 05:14 PM White William Richard Chief Financial Officer Sep 10 '24 Sale 26.18 639 16,729 41,152 Sep 13 05:13 PM Rolph Timothy Chief Scientific Officer Sep 10 '24 Sale 26.18 537 14,059 180,705 Sep 13 05:11 PM Cheng Andrew President and CEO Sep 10 '24 Sale 26.18 1,738 45,501 605,417 Sep 13 05:10 PM Young Jonathan Chief Operating Officer Sep 03 '24 Sale 26.72 5,000 133,588 236,854 Sep 05 04:08 PM Yale Catriona Chief Development Officer Sep 03 '24 Option Exercise 0.61 949 584 76,880 Sep 05 04:05 PM Yale Catriona Chief Development Officer Sep 03 '24 Sale 27.61 949 26,206 75,931 Sep 05 04:05 PM White William Richard Chief Financial Officer Aug 26 '24 Option Exercise 14.57 75,159 1,095,329 74,462 Aug 29 04:30 PM White William Richard Chief Financial Officer Aug 27 '24 Option Exercise 21.09 23,175 488,761 64,966 Aug 29 04:30 PM White William Richard Chief Financial Officer Aug 26 '24 Sale 27.21 75,159 2,045,152 41,791 Aug 29 04:30 PM White William Richard Chief Financial Officer Aug 27 '24 Sale 26.41 23,175 612,098 41,791 Aug 29 04:30 PM Yale Catriona Chief Development Officer Aug 23 '24 Option Exercise 0.61 8,851 5,443 84,782 Aug 28 11:11 AM Yale Catriona Chief Development Officer Aug 26 '24 Option Exercise 0.61 5,200 3,198 81,131 Aug 28 11:11 AM Yale Catriona Chief Development Officer Aug 23 '24 Sale 27.53 8,851 243,641 75,931 Aug 28 11:11 AM Yale Catriona Chief Development Officer Aug 26 '24 Sale 27.51 5,200 143,073 75,931 Aug 28 11:11 AM White William Richard Officer Aug 26 '24 Proposed Sale 27.46 98,334 2,700,252 Aug 26 04:32 PM CATRIONA YALE Officer Aug 23 '24 Proposed Sale 26.11 15,000 391,650 Aug 23 04:27 PM
Index RUT P/E - EPS (ttm) -2.19 Insider Own 20.06% Shs Outstand 57.29M Perf Week 3.31%
Market Cap 340.98M Forward P/E - EPS next Y -2.65 Insider Trans -4.30% Shs Float 54.62M Perf Month -12.15%
Income -122.68M PEG - EPS next Q -0.64 Inst Own 84.44% Short Float 15.40% Perf Quarter -42.18%
Sales 0.00M P/S - EPS this Y -7.49% Inst Trans 0.73% Short Ratio 7.39 Perf Half Y -59.33%
Book/sh 3.47 P/B 1.44 EPS next Y -15.38% ROA -46.92% Short Interest 8.41M Perf Year -65.20%
Cash/sh 3.14 P/C 1.59 EPS next 5Y -13.34% ROE -51.76% 52W Range 4.60 - 16.62 Perf YTD -14.41%
Dividend Est. - P/FCF - EPS past 5Y -105.28% ROI -61.50% 52W High -69.98% Beta 2.06
Dividend TTM - Quick Ratio 7.10 Sales past 5Y 0.00% Gross Margin - 52W Low 8.48% ATR (14) 0.45
Dividend Ex-Date - Current Ratio 7.10 EPS Y/Y TTM 5.80% Oper. Margin - RSI (14) 38.97 Volatility 5.98% 8.15%
Employees 74 Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 28.00
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -26.21% Payout - Rel Volume 0.44 Prev Close 5.08
Sales Surprise - EPS Surprise -5.08% Sales Q/Q - Earnings Nov 12 AMC Avg Volume 1.14M Price 4.99
SMA20 -11.58% SMA50 -16.03% SMA200 -51.70% Trades
Volume 505,202 Change -1.77%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-02-24 Initiated Goldman
Buy
$24
Jan-30-24 Initiated Citigroup
Buy
$20
Jul-21-23 Initiated Oppenheimer
Outperform
$21
May-05-23 Initiated CapitalOne
Overweight
$16
Feb-22-23 Initiated Credit Suisse
Outperform
$12
Jul-06-22 Resumed Canaccord Genuity
Buy
$16
Jun-09-22 Upgrade H.C. Wainwright
Neutral → Buy
$12
Feb-28-22 Initiated H.C. Wainwright
Neutral
Dec-07-21 Resumed Cowen
Outperform
Dec-14-20 Initiated JP Morgan
Overweight
$52
Dec-14-20 Initiated Jefferies
Buy
$70
Dec-14-20 Initiated Cowen
Outperform
Dec-14-20 Initiated Canaccord Genuity
Buy
$60
Show Previous Ratings
Feb-19-25 04:30PM
Feb-18-25 07:00AM
Feb-04-25 04:30PM
Feb-03-25 04:30PM
Jan-03-25 04:30PM
(GlobeNewswire) +5.75%
-6.62%
07:00AM
Loading…
Jan-02-25 07:00AM
Dec-10-24 07:00AM
Dec-09-24 07:00AM
Dec-03-24 04:30PM
09:17AM
(Pharmaceutical Technology)
Dec-02-24 07:00AM
Nov-25-24 05:30PM
Nov-24-24 07:27PM
Nov-12-24 04:01PM
Nov-06-24 07:01AM
04:44PM
Loading…
Nov-04-24 04:44PM
Oct-23-24 07:00AM
Oct-09-24 07:00AM
Oct-02-24 04:30PM
Sep-04-24 04:49PM
Aug-21-24 07:00AM
Aug-06-24 04:02PM
Aug-02-24 04:30PM
Aug-01-24 08:50AM
Jul-02-24 04:29PM
Jun-14-24 07:05PM
Jun-04-24 04:28PM
May-28-24 07:03AM
May-15-24 07:01AM
May-08-24 10:58PM
04:02PM
Loading…
04:02PM
07:02AM
May-03-24 12:15PM
May-02-24 04:37PM
May-01-24 07:02AM
Apr-08-24 04:30PM
Apr-05-24 12:16AM
Apr-02-24 04:29PM
Mar-11-24 04:03PM
Mar-06-24 07:03AM
Mar-04-24 04:30PM
Feb-06-24 07:01AM
Feb-02-24 04:30PM
Jan-22-24 10:54AM
Jan-08-24 08:12AM
Jan-02-24 04:01PM
Dec-21-23 10:59AM
Dec-05-23 12:27PM
Dec-04-23 04:29PM
Dec-01-23 09:30AM
Nov-28-23 05:10PM
Nov-27-23 12:54PM
11:32AM
Nov-22-23 09:00AM
(Investor's Business Daily)
Nov-07-23 04:02PM
Nov-02-23 04:32PM
(GlobeNewswire) +5.35%
+5.40%
Nov-01-23 04:27PM
Oct-30-23 08:50AM
Oct-26-23 10:33AM
Oct-22-23 02:55AM
Oct-20-23 01:15PM
Oct-17-23 07:01AM
Oct-16-23 07:02AM
Oct-12-23 07:01AM
Oct-11-23 09:55AM
08:50AM
Oct-10-23 07:00AM
Oct-03-23 04:30PM
Sep-27-23 09:24PM
Sep-25-23 09:55AM
08:50AM
Sep-20-23 07:29AM
Sep-15-23 01:09PM
Sep-14-23 11:02PM
Sep-08-23 12:00PM
09:55AM
Sep-07-23 04:02PM
Sep-06-23 04:30PM
Sep-05-23 04:30PM
07:30AM
Aug-08-23 04:03PM
08:23AM
Aug-02-23 04:30PM
Aug-01-23 08:00AM
Jul-05-23 07:30AM
Jun-14-23 01:00PM
Jun-02-23 04:30PM
May-30-23 04:30PM
May-19-23 06:29AM
May-11-23 08:43AM
May-09-23 04:01PM
(GlobeNewswire) +10.65%
-8.67%
May-08-23 07:06AM
May-02-23 04:30PM
Apr-13-23 04:30PM
Apr-04-23 04:30PM
Mar-09-23 04:00PM
Mar-02-23 05:00PM
04:05PM
Feb-21-23 04:30PM
(GlobeNewswire) -8.57%
+9.62%
Feb-02-23 06:00PM
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bain Capital Life Sciences Inv 10% Owner Jan 08 '25 Buy 5.76 300,000 1,727,370 7,800,000 Jan 13 04:34 PM Graham G. Walmsley Director Dec 17 '24 Sale 6.75 700,761 4,730,137 0 Dec 17 07:52 PM Zojwalla Naseem CHIEF MEDICAL OFFICER Dec 16 '24 Option Exercise 4.87 14,000 68,180 129,509 Dec 17 07:29 PM Logos Opportunities Fund I LP Affiliate Dec 13 '24 Proposed Sale 6.75 700,761 4,730,137 Dec 13 04:37 PM Harmon Cyrus Director Dec 10 '24 Sale 9.37 8,256 77,359 772,277 Dec 11 07:56 PM Harmon Cyrus Director Dec 11 '24 Sale 8.68 8,137 70,597 764,140 Dec 11 07:56 PM Myles David C. CH. DISCOV. & NON-CLIN DEV OFF Dec 11 '24 Sale 8.68 13,614 118,116 598,333 Dec 11 07:56 PM Myles David C. CH. DISCOV. & NON-CLIN DEV OFF Dec 10 '24 Sale 9.38 12,452 116,800 611,947 Dec 11 07:56 PM Zojwalla Naseem CHIEF MEDICAL OFFICER Dec 11 '24 Sale 8.68 14,522 125,994 115,509 Dec 11 07:54 PM Zojwalla Naseem CHIEF MEDICAL OFFICER Dec 10 '24 Sale 9.37 13,283 124,462 130,031 Dec 11 07:54 PM Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. Dec 11 '24 Sale 8.68 18,356 159,259 543,549 Dec 11 07:53 PM Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. Dec 10 '24 Sale 9.37 16,803 157,444 561,905 Dec 11 07:53 PM Bohen Sean PRESIDENT AND CEO Dec 11 '24 Sale 8.68 57,174 496,052 241,662 Dec 11 07:52 PM Bohen Sean PRESIDENT AND CEO Dec 10 '24 Sale 9.37 52,328 490,313 298,836 Dec 11 07:52 PM Harmon Cyrus Director Dec 11 '24 Proposed Sale 8.68 8,137 70,635 Dec 11 05:19 PM Kovacs Shane William Charles Officer Dec 11 '24 Proposed Sale 8.68 18,356 159,345 Dec 11 05:04 PM Myles David C. Officer Dec 11 '24 Proposed Sale 8.68 13,614 118,180 Dec 11 04:52 PM Zojwalla Naseem Officer Dec 11 '24 Proposed Sale 8.68 14,522 126,062 Dec 11 04:33 PM Bohen Sean Officer Dec 11 '24 Proposed Sale 8.68 57,174 496,322 Dec 11 04:27 PM Bohen Sean Officer Dec 10 '24 Proposed Sale 9.37 52,328 490,241 Dec 10 03:23 PM Myles David C. Officer Dec 10 '24 Proposed Sale 9.38 12,452 116,748 Dec 10 02:48 PM Harmon Cyrus Director Dec 10 '24 Proposed Sale 9.37 8,256 77,367 Dec 10 02:38 PM Kovacs Shane William Charles Officer Dec 10 '24 Proposed Sale 9.37 16,803 157,426 Dec 10 02:21 PM Zojwalla Naseem Officer Dec 10 '24 Proposed Sale 9.37 13,283 124,517 Dec 10 02:14 PM Kovacs Shane William Charles Ch. Operating & Financial Off. Nov 15 '24 Option Exercise 7.02 25,000 175,500 510,458 Nov 18 06:00 AM Paradigm Biocapital Advisors L 10% Owner Aug 01 '24 Sale 14.91 2,400,000 35,796,000 783,118 Aug 05 04:30 PM Harmon Cyrus Director Jul 29 '24 Sale 15.58 4,066 63,348 752,217 Jul 31 05:15 PM Harmon Cyrus Director Jul 30 '24 Sale 15.55 934 14,524 751,283 Jul 31 05:15 PM Harmon Cyrus Director Jul 30 '24 Proposed Sale 15.55 934 14,526 Jul 30 04:15 PM Harmon Cyrus Director Jul 29 '24 Proposed Sale 15.58 4,066 63,352 Jul 29 04:23 PM Harmon Cyrus Director Jul 11 '24 Sale 12.26 5,000 61,300 756,283 Jul 12 05:15 PM Harmon Cyrus Director Jun 28 '24 Sale 10.77 20,000 215,400 761,283 Jul 02 05:30 PM Graham G. Walmsley Director Jun 04 '24 Sale 14.85 1,175,000 17,448,750 700,761 Jun 06 05:01 PM Harmon Cyrus Director May 31 '24 Sale 9.41 15,000 141,150 791,283 Jun 04 09:00 PM Harmon Cyrus Director Jun 04 '24 Sale 12.33 5,000 61,650 781,283 Jun 04 09:00 PM Harmon Cyrus Director Jun 03 '24 Sale 10.93 5,000 54,650 786,283 Jun 04 09:00 PM Zojwalla Naseem CHIEF MEDICAL OFFICER May 24 '24 Option Exercise 4.87 9,460 46,070 89,824 May 28 05:00 PM Harmon Cyrus Director May 06 '24 Sale 10.92 5,000 54,600 806,283 May 07 05:00 PM Harmon Cyrus Director Apr 30 '24 Sale 9.51 15,000 142,650 811,283 May 02 05:09 PM Harmon Cyrus Director Mar 28 '24 Sale 10.97 20,000 219,400 826,283 Mar 29 05:00 PM Zojwalla Naseem CHIEF MEDICAL OFFICER Mar 18 '24 Option Exercise 4.87 13,700 66,719 80,364 Mar 20 05:30 PM Harmon Cyrus Director Feb 29 '24 Sale 12.41 25,000 310,309 846,283 Mar 04 05:30 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
